Clinical trials: Neoplasms, Squamous Cell
Head and Neck Cancer, Neoadjuvant Therapy
Application of MRI Radiomics Features in Neoadjuvant Therapy of Head and Neck Squamous Cell Carcinoma
Head and neck squamous cell carcinoma is the sixth most common malignant tumor in the world. Neoadjuvant therapy, including neoadjuvant chemotherapy and immunotherapy, is recommended for patients with locally advanced head and…
- Conditions
- Head and Neck Cancer, Neoadjuvant Therapy, Immunotherapy, Chemotherapy
- Trial name
- NCT06755567
- Testing
- MRI-based radiomics-clinical model
- Where
- China
- Volunteers
- 750 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Locally Advanced Esophageal Squamous Cell Carcinoma, Sintilimab
Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma
At present, concurrent chemoradiotherapy (cCRT) with platin-based dual-drug regimen is the standard treatment for inoperable, locally advanced esophageal cancer in patients with a good performance status.
- Conditions
- Locally Advanced Esophageal Squamous Cell Carcinoma, Sintilimab, Radiotherapy, Concurrent Chemoradiotherapy
- Trial name
- NCT06342167
- Testing
- Radiotherapy, Programmed Cell Death Protein 1 Inhibitor, Immunonutrition support
- Where
- 10 sites in China
- Volunteers
- 57 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Head and Neck Squamous Cell Carcinoma
Neoadjuvant Adebrelimab Plus Dalpiciclib in Head and Neck Squamous Cell Carcinoma
This study is a single arm phase II trial including 30 patients with III-IVB (according to the 8th edition of UICC/AJCC staging) locally advanced head and neck squamous cell carcinoma (HNSCC) eligible for resection, who receive…
- Trial name
- NCT06199271
- Testing
- Adebrelimab and dalpiciclib
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Zhongzheng Xiang
Head and Neck Squamous Cell Carcinoma
A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC
The purpose of the study is to determine the activity and safety of ACR-368 (prexasertib) in combination with gemcitabine in participants with Head and Neck Squamous Cell Carcinoma (HNSCC).
- Trial name
- NCT06597565
- Testing
- Gemcitabine, ACR-368
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Squamous Cell Carcinoma of the Head and Neck
A Study of Nivolumab in Participants With Squamous Cell Carcinoma of the Head & Neck (SCCHN) - Patient Reported Outcomes (PRO)
The purpose of the study is to capture the utilization of nivolumab among participants with squamous cell carcinoma of the head and neck (SCCHN) since its approval, and to describe the health related quality of life (HRQoL) among…
- Trial name
- VOLUME-PRO (NCT05068609)
- Testing
- Nivolumab
- Where
- United States
- Volunteers
- 509 people
- Sponsor
- Bristol-Myers Squibb
Esophageal Neoplasms
Study of Simultaneous Modulated Accelerated Radiation Therapy Concurrent With Chemotherapy to Treat Esophageal Cancer
The purpose of this study is to evaluate the acute and 2-year late toxicities, the 2-year local control and overall survival rates in patients with esophageal squamous cell carcinoma receiving simultaneous modulated accelerated…
- Trial name
- NCT01670409
- Testing
- SMART, PF
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Chuangzhen Chen
Oral Squamous Cell Carcinoma
A Study of TC(Docetaxel and Carboplatin) Regimen With or Without Nimotuzumab in Recurrent Metastatic Oral Squamous Cell Carcinoma
This prospective, single-center, randomized, controlled study will evaluate the efficacy and safety of TC Regimenwith or without nimotuzumab in recurrent metastatic oral squamous cell carcinoma.
- Trial name
- NCT04367909
- Testing
- Nimotuzumab, Docetaxel, Carboplatin
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Xin-Hua Xu
Paranasal Sinus Cancer, Nasal Cavity Tumor
A Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal Passages
This study is being done to test a new treatment plan for large tumors in the sinus or nasal cavity that will include endoscopic surgery plus chemotherapy and proton-beam radiation therapy.
- Conditions
- Paranasal Sinus Cancer, Nasal Cavity Tumor, Nasal Cavity Adenocarcinoma
- Trial name
- NCT03274414
- Testing
- Cisplatin, Adjuvant Proton Radiotherapy, Endoscopic Resection
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lung Cancer
Combination Chemotherapy Followed by Surgery in Treating Patients With Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug with surgery may kill more tumor cells.
- Trial name
- NCT00003231
- Testing
- cisplatin, docetaxel, surgical procedure
- Where
- 9 sites in Switzerland
- Volunteers
- 40 people
- Sponsor
- Swiss Cancer Institute
Cervical Cancer
EF5 to Detect Tumor Hypoxia in Patients With Stage IIB, Stage IIIB, or Stage IVA Cervical Cancer
RATIONALE: Knowing the level of oxygen in tumor tissue may help predict the effectiveness of anticancer therapy. EF5 may be effective in measuring oxygen in tumor tissue and helping to predict the effectiveness of anticancer…
- Trial name
- NCT00049231
- Testing
- EF5, immunohistochemistry staining method, biopsy
- Where
- 5 sites in United States
- Sponsor
- Gynecologic Oncology Group
Squamous Cell Carcinoma of the Head and Neck
FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel
The primary objective of the phase II trial is to determine the efficacy and safety of a combination of Durvalumab with the Carboplatin/Paclitaxel as first line treatment in patients with recurrent/metastatic SCCHN not eligible…
- Trial name
- FRAIL-IMMUNE (NCT03723967)
- Testing
- Durvalumab with Carboplatin/Paclitaxel
- Where
- 17 sites in France
- Volunteers
- 104 people
- Sponsor
- Centre Leon Berard
Head and Neck Squamous Cell Carcinoma
Chemoprevention of Head and Neck Squamous Cell Carcinoma (HNSCC) With Valproic Acid
This study evaluates the addition of valproic acid as a chemopreventive drug in head and neck squamous cell carcinoma (HNSCC) patients that do not have signs of recurrence or residual disease.
- Trial name
- GAMA (NCT02608736)
- Testing
- Valproic Acid
- Where
- Brazil
- Volunteers
- 42 people
- Sponsor
- Barretos Cancer Hospital
Esophageal Malignant Neoplasm Primary
Prospective Phase II Clinical Study of Neoadjuvant Chemoradiotherapy Combined With PD-1/PD-L1 Inhibitors in the Treatment of Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
A prospective trial design was used to evaluate the efficacy and safety of neoadjuvant chemoradiotherapy combined with PD-1/PD-L1 inhibitors in the treatment of locally advanced resectable esophageal squamous cell carcinoma.
- Trial name
- LA-ESCC (NCT06888531)
- Testing
- Neoadjuvant chemoradiotherapy combined with PD-1/PD-L1 inhibitors for the treatment of locally advanced resectable esophageal squamous cell carcinoma
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Henan Cancer Hospital
Stage III Oral Cavity Squamous Cell Carcinoma, Stage IVA Oral Cavity Squamous Cell Carcinoma
TPF Induction Chemotherapy for Locally Advanced and Resectable Oral Squamous Cell Carcinoma
Induction chemotherapy is regarded as an effective way to reduce or downgrade the locally advanced or aggressive cancers, and to improve the chance of eradication of the locoregional lesions by radical surgery and/or…
- Trial name
- NCT01542931
- Testing
- TPF induction chemotherapy
- Where
- China
- Volunteers
- 256 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Squamous Cell Carcinoma of the Head and Neck
A Phase II Study to Evaluate Low-Dose Fractionated Radiotherapy (LDFRT)
The purpose of this study is to determine if low-dose radiation therapy and the chemotherapy drug paclitaxel is effective in treating head and neck cancer that has returned after treatment with standard radiation therapy alone…
- Trial name
- NCT01820312
- Testing
- Low-Dose Fractionated Radiation Therapy/Paclitaxel
- Where
- United States
- Sponsor
- University of Arkansas
Esophageal Cancer
Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell
The purpose of this study is to observe and evaluate the efficacy and safety of Anti-PD-1 antibody SHR-1210 plus apatinib versus SHR-1210 as second-line treatment of advanced esophageal squamous cell.
- Trial name
- NCT05049681
- Testing
- Camrelizumab, Apatinib
- Volunteers
- 234 people, healthy volunteers welcome
- Sponsor
- Feng Wang
Esophageal Squamous Cell Carcinoma
Phase II Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy for Esophageal Squamous Cell Carcinoma
The primary object of this trial is to evaluate the 2-year local control rate adding extensive clinical target volumes in postoperative radiotherapy for esophageal squamous cell carcinoma.
- Trial name
- NCT02384811
- Testing
- radiation
- Where
- 2 sites in China
- Volunteers
- 70 people
- Sponsor
- Fudan University
Non-small Cell Lung Cancer Stage IV
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
The goal of this clinical trial is to confirm that SB27 works in the same way as Keytruda in metastatic non-squamous non-small cell lung cancer (NSCLC) patients.
- Trial name
- NCT06348199
- Testing
- SB27, Keytruda
- Where
- 93 sites in Bosnia and Herzegovina, Brazil and 12 more
- Volunteers
- 555 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Metastatic Non Small Cell Lung Cancer
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed and platinum chemotherapy in participants with no…
- Trial name
- NCT05555732
- Testing
- Datopotamab Deruxtecan, Pembrolizumab, Pemetrexed
- Where
- 260 sites in United States, Argentina and 27 more
- Volunteers
- 1,170 people
- Sponsor
- Daiichi Sankyo
Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer
Study of XB010 in Subjects With Solid Tumors
This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic…
- Conditions
- Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer, Head and Neck Squamous Cell Cancer, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- NCT06545331
- Testing
- XB010, Pembrolizumab
- Where
- 20 sites in United States, United Kingdom
- Volunteers
- 396 people
- Sponsor
- Exelixis